Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy

Trial Profile

A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs TAK 935 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ENDYMION
  • Sponsors Takeda
  • Most Recent Events

    • 25 Sep 2018 Planned End Date changed from 19 Dec 2020 to 21 Mar 2023.
    • 25 Sep 2018 Planned primary completion date changed from 18 Jul 2020 to 21 Mar 2023.
    • 15 Aug 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top